TC Biopharm Holdings PLC

TC Biopharm (Holdings) Plc is a clinical-stage biopharmaceutical company, which engages in the development of novel immunotherapy products based on its proprietary allogeneic gamma delta T cell platform. The company was founded by Michael Leek and Angela Scott in 2013 and is headquartered in Motherwell, the United Kingdom.

Earnings data Q1 2024

Earnings data Q3 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

The Arena Group Holdings

Heartcore Enterprises

Renaissance IPO ETF

Renaissance International IPO ETF

Modular Medical

Snowflake

Uber

The Arena Group, a media holding company operating Sports Illustrated, TheStreet, and other brands, raised $30 million at a $172 million market cap. Nine SPACs went public this past week.

U.S. IPO Weekly Recap: 3 Micro-Cap IPOs Come To Market During The February Lull

Ambev

New Gold

Southwestern Energy

MannKind

5 must watch penny stocks that you should know about in February The post 5 ‘Must Watch' Penny Stocks For February 2022 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

5 ‘Must Watch' Penny Stocks For February 2022

EDINBURGH, Scotland, Feb. 11, 2022 /PRNewswire/ -- TC BioPharm (Holdings) plc ("TC BioPharm"), a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and viral indications is pleased to announce that American Depositary Shares representing the Company's ordinary shares will commence trading today on the Nasdaq Capital Market (the "Nasdaq") under the ticker symbol "TCBP". TC BioPharm is developing safe, cost-effective cell therapies for cancer and severe viral infection.

TC BioPharm Begins Trading on Nasdaq Today Under Symbol "TCBP"

News for TC Biopharm Holdings PLC Stock (TCBP)